No profile data available.
Jazz Pharmaceuticals plc (JAZZ) is a healthcare company in the brain and nerve treatment drugs industry, based in Dublin, Ireland, with about 2,890 full-time employees.
It reported revenue of $4.27 billion for fiscal year 2025, up 4.9% from fiscal year 2024, and net income of -$356.15 million. In Q2 2026 (the quarter ended June 30, 2026) revenue was $1.21 billion, up 15.5% from a year before. United States was its largest region in fiscal year 2025, with 90% of revenue. Its market capitalization was $14.18 billion as of October 9, 2026.
Figures from company filings and market data; latest fiscal year ended December 31, 2025; market data as of October 9, 2026.
Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products in the United States, Europe, and internationally.
Jazz Pharmaceuticals reported $4.27 billion in revenue for fiscal year 2025, up 4.9% from $4.07 billion in fiscal year 2024. In Q2 2026 revenue was $1.21 billion.
United States: 90% of revenue by region in fiscal year 2025, followed by Europe (8%).
$14.18 billion as of October 9, 2026.
Listed companies of a similar size in the same industry (brain and nerve treatment drugs) include argenx SE (ARGX), Biogen Inc. (BIIB), Neurocrine Biosciences, Inc. (NBIX), Axsome Therapeutics, Inc. (AXSM).